Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
5 papers
Researchers pooled results from 205 intravenous ketamine infusions (0.5 mg/kg given over 40 minutes) in 97 people with treatment-resistant major depression. About two thirds (67%, 65 of 97) showed a strong antidepressant response (≥50% improvement). Most side effects happened in the first 4 hours and were short-lived. Few infusions were…
This systematic review looked at studies of ketamine for people whose depression did not respond to usual treatments (treatment-resistant depression, TRD). Across 24 papers with 416 patients, most studies found that ketamine can reduce depressive symptoms quickly — often within hours — and it was also reported to lower suicidal…
A single low-dose intravenous infusion of ketamine can relieve core symptoms of major depression within about two hours, with effects that can last up to two weeks. Research in animals links this fast effect to ketamine blocking NMDA receptors that are active at rest, which lowers eEF2 kinase activity and…
Major depressive disorder is a serious illness. Researchers reviewed how ketamine — a drug that blocks a brain receptor called the NMDA receptor — can lift depression symptoms quickly and for a sustained time in people and in animals. They describe possible ways ketamine works: it may boost another type…
Major depressive disorder (MDD) is a serious psychiatric illness that causes functional impairment in many people. While monoaminergic antidepressants have been used to effectively treat MDD, these antidepressants have limitations in that they have delayed onset of action and many patients remain treatment-resistant. Therefore, there is a need to develop…
